Cannabis thérapeutique : la France tente l’expérience Le Quotidien du Pharmacien, 6 janvier 2020 - N°3567 By Damien Coulomb https://reputation.kantar.com//Public/IndexReview?ticket=B0676A6A0861C43FAA8FF14D942445F772837649EBF3AE141B18755109B597E279FDFAD2E9DA3F6A339F855835E70A2BA4435547C70966B06357667834105870033911B7545D63C0FA495FAE3543451038F55FF11906571C7AF35F378C6A16BAD3ED49B0933F8B41D99A90532AE551334818943393DA3A4BB381D488EDF9A29E Le 3 décembre dernier, les députés adoptaient définitivement la loi de financement de la sécurité sociale 2020. Un des amendements du texte, proposé par le député de l'Isère Olivier Véran, inscrit dans la loi l’expérimentation du cannabis thérapeutique dans le traitement d’un certain nombre d’indications. À partir du premier semestre 2020, les patients Français pourront se voir prescrire du cannabis thérapeutique dans le cadre d’une expérimentation de 2 ans.Selon le descriptif fourni par le comité scientifique spécialisé temporaire (CSST) rassemblé par l’Agence nationale de [...]
Lire la suiteThe Confrontation between Ethnopharmacology and Pharmacological Tests of Medicinal Plants Associated with Mental and Neurological Disorders Giovanna Felipe Cavalcante e Costa, Hisao Nishijo, Leonardo Ferreira Caixeta, and Tales Alexandre Aversi-Ferreira Hindawi - Evidence-Based Complementary and Alternative Medicine, Volume 2018, Article ID 7686913, 27 pages Doi : 10.1155/2018/7686913 Abstract For neurological disorders, pharmacological tests have shown promising results in the reduction of side effects when using plants with known therapeutic effects in the treatment of some types of dementia. Therefore, the goals of this study are to gather data about the major medicinal plants used in the nervous system as described in ethnopharmacological surveys from South [...]
Lire la suiteTranslational evidence for ayahuasca as an antidepressant : what’s next ? Rafael Guimaraes dos SANTOS, José Carlos BOUSO British Journal of Psychiatry, 2019, 41, (4), 275-276. Doi : 10.1590/1516-4446-2019-4104 Depression is among the most important contributors to global disability and suicidal deaths. Available antidepressants are usually selective inhibitors of serotonin and norepinephrine uptake, which need weeks of daily intake before therapeutic effects appear, have limited efficacy for many patients, and induce significant adverse reactions after prolonged use. Therefore, recent research has focused on finding new antidepressant compounds that are fast-acting, more effective, and less toxic. The article recently published by da Silva et al. in the [...]
Lire la suited-Lysergic acid diethylamide has major potential as a cognitive enhancer Felipe Augusto Cini, Isis Ornelas, Encarni Marcos, Livia Goto-Silva, Juliana Nascimento, Sergio Ruschi, José Salerno, Karina Karmirian, Marcelo Costa, Eduardo Sequerra, Dráulio de Araújo, Luis Fernando Tófoli, César Rennó-Costa, Daniel Martins-de-Souza, Amanda Feilding, Stevens Rehen, Sidarta Ribeiro BioRxiv, 6 december 2019. Doi : 10.1101/866814 Abstract Psychedelic agonists of serotonin receptors induce neural plasticity and synaptogenesis, but their potential to enhance learning remains uncharted. Here we show that a single dose of d-LSD, a potent serotonergic agonist, increased novel object preference in young and adult rats several days after treatment. d- LSD alone did not increase preference [...]
Lire la suiteRegular Cannabis Use Linked to Cardiac Abnormalities Fran Lowry Medscape - Dec 30, 2019. https://www.medscape.com/viewarticle/923220?nlid=133282_2052&src=WNL_mdplsnews_200103_mscpedit_psyc&uac=292598PZ&spon=12&impID=2232271&faf=1 Regular recreational use of cannabis is associated with potentially adverse features of left ventricular size and subclinical impairment of left ventricular function, compared with rare or no cannabis use, an observational study concludes. Previous use of recreational cannabis was not associated with such features, suggesting that any deleterious effects may not be permanent. "These are early data which included a relatively small group of regular cannabis users, and the changes we detected were subtle," lead author Mohammed Y. Khanji, MBBCh, PhD, William Harvey Research Institute, NIHR Barts Biomedical Center, Queen Mary University of London, and [...]
Lire la suiteÉtudes psychédéliques Vincent Verroust, doctorant à l'EHESS ( CAK )Cet enseignant est référent pour cette UE https://enseignements-2019.ehess.fr/2019/ue/2998/ Mardi de 18 h à 19 h 30 (amphithéâtre Rouelle, Muséum national d'Histoire naturelle, 57 rue Cuvier 75005 Paris), les 26 novembre, 17 décembre 2019, 28 janvier, 25 février, 31 mars, 28 avril, 26 mai et 30 juin 2020 Plan pour trouver l'amphi : https://drive.google.com/file/d/1h-oVy6oTh7UTMh84X-o448VhCCmBMp-M/view?usp=sharing NB : merci d'arriver en avance pour éviter de trouver portes closes. Le terme psychedelic a été forgé en 1956 par le psychiatre britannique Humphry Osmond (1917 - 2004) pour qualifier les effets psychiques de la mescaline et du LSD, deux substances psychotropes sur lesquelles [...]
Lire la suiteCannabis Use Rising Faster Among Depressed Americans Lisa Rapaport Medscape - Dec 26, 2019. https://www.medscape.com/viewarticle/923160?nlid=133282_2052&src=WNL_mdplsnews_200103_mscpedit_psyc&uac=292598PZ&spon=12&impID=2232271&faf=1 (Reuters Health) - Regular cannabis use has risen more quickly among people with depression, and they're less likely to perceive it as risky, compared with people who aren't depressed, a U.S. study suggests. Researchers examined data collected from a total of almost 729,000 people aged 12 years and older between 2005 and 2017, including any prior-month cannabis use and any depression experienced over the previous year. By the final year of the study, about 19% of people with depression reported at least some cannabis use, compared with 8.7% of individuals without a recent history of [...]
Lire la suiteTwitter Bots Tout Cannabis as a Cure-all Despite Few Approved Medical Uses Lisa Rapaport Medscape - Dec 27, 2019. https://www.medscape.com/viewarticle/923184?nlid=133282_2052&src=WNL_mdplsnews_200103_mscpedit_psyc&uac=292598PZ&spon=12&impID=2232271&faf=1 (Reuters Health) - Social media bots are promoting cannabis as a remedy for everything from cancer to insomnia and foot pain, according to an analysis of posts on Twitter. "Social bots regularly perpetuate unsubstantiated health claims on the platform, providing one example of how false statements may drown out solid science on social media," said lead study author Jon-Patrick Allem of the Keck School of Medicine at the University of Southern California in Los Angeles. "I want the public to be aware of the difference between a demonstrated, scientifically backed [...]
Lire la suiteCannabis : saurez-vous bien faire la distinction entre le «bien-être» et la «récréation» ? Jean-Yves NAU Blog Le Monde, 23 décembre 2019 Bonjour Est-ce une nouvelle tentative pour dépénaliser/légaliser une substance illicite mais très largement consommée ? L’Assemblée nationale vient de créér une « Mission d’information commune sur la réglementation et l’impact des différents usages du cannabis ». Une mission composée de trente-trois députés et issue des réflexions de … six commissions (affaires économiques, affaires sociales, lois, finances, affaires culturelles et éducatives, développement durable). Pourquoi développer une telle énergie législative ? Parce qu’ « en France la réglementation des usages du cannabis a particulièrement évolué ces dix dernières années » [il s’agit de [...]
Lire la suiteAustralia should be initiating a psychedelic research program : What are the barriers ? Nigel Strauss, Stephen J Bright and Martin L Williams Australian & New Zealand Journal of Psychiatry, 2016, Vol. 50, (11), 1036–1037 DOI: 10.1177/0004867416670520 A recent review in Pharmacological Reviews highlights that over the last decade, a renaissance has occurred in psychedelic drug research in North America and Europe as investigators at Johns Hopkins School of Medicine, University of California, Los Angeles (UCLA), New York University and Imperial College London have embarked on studies that could be paradigm-changing for psychiatry (Nichols, 2016). These developments overturn a 30-year embargo on psychedelic research [...]
Lire la suite